

Complications of minimal invasive surgery for rectal cancer - a systematic review

Benjamin Sejr Thinggaard¹, MD, Sharaf Karim Perdawood¹, MD

¹ Department of Surgery, Slagelse Hospital, Denmark

Correspondence: Benjamin Thinggaard, Department of Surgery, Slagelse Hospital, Denmark.

E-mail: bthi@regionsjaelland.dk, phone: +45 51942270

ABSTRACT

Background: Total Mesorectal Excision (TME) is widely accepted as the standard surgical treatment for mid and low rectal cancer. The robotic (RoTME) and laparoscopic (LaTME) approaches to treat rectal cancer are shown to be feasible. Transanal TME (TaTME) is the most recent minimal invasive approach with promising results. We aimed to review the peri and postoperative complications associated with the three approaches.

Methods: A systematic search in the PubMed and Embase databases was performed. Both authors assessed the studies for eligibility. Clinical randomized as well as non-randomized studies published during the last six years were included.

Results: In total 39 studies (8094 patients) met the inclusion criteria. The LaTME had low rates of urinary complications, high rates of wound infection and intraabdominal abscesses. The RoTME had high rates of anastomotic leakages, but low rates of several other complications like; ureter and bladder injuries, bleeding and thirty-day mortality. The anastomosis performed more efficiently after TaTME with lower rates of anastomotic leakages, but higher rates of bleeding and 30-days mortality.

Conclusions: The procedures each performed well in relation to the different complications however further research especially concerning TaTME and RoTME is needed. Focus on which procedure who best treats a specific tumor stage, tumor location and type of patient could possibly reduce complications and postoperative mortality in the future.

Keywords: rectal cancer; complications; total mesorectal excision; transanal; robot-assisted surgery; laparoscopic surgery

INTRODUCTION

Rectal cancer is the fifth most common type of cancer in Denmark and less than 2 out of 3 will survive more than 5 years after diagnosis (1). Significant advances have been achieved in the treatment of rectal cancer over the past three decades. The introduction of TME (2), and improved preoperative diagnostic work-up have improved the short- and long-term results (3, 4). TME is widely accepted as the standard surgical treatment for mid and low rectal cancer (3-5).

It is general acknowledged that the laparoscopic approach for the treatment of rectal cancer has more advantages than open surgery with faster recovery, shorter hospital stays, decreased blood loss, infection rates and multi-organ failure as well as comparable long-term outcomes (6-11). However, LaTME is a technically difficult procedure in obese patients, males and patients with a narrow pelvis (12, 13).

RoTME is a feasible approach with potential advantages compared with laparoscopy and open surgery (14-17), and is reported to be equivalent to laparoscopic surgery with respect to the short-term perioperative and oncologic outcomes (15, 18, 19). However, the true cost-benefit advantages still are questionable (12, 20, 21), and results of a randomized trial are awaited (22). As the newest approach, TaTME shows promising results as a safe and effective technique with acceptable short-term outcomes (23, 24).

Perioperative complications play an important role in the adoption of the appropriate approach, like both the pathological outcomes and the complication rates do. The aim of this review is to highlight common and severe reported complications associated with LaTME, RoTME and TaTME.

MATERIALS AND METHODS

A systematic search was conducted in PubMed and Embase databases on October 7 2016 using the following words separately and in combination: “complication”, “surgery”, “rectal”, “cancer”, “total mesorectal excision”, “transanal”, “TaTME”, “laparoscopic” and “robotic”. Only full text articles in English were included. The search and the review processes were undertaken by the two authors using the PRISMA guidelines (25). The search identified 147 clinical trials. After crosschecking the reference lists 24 additional articles were retrieved. After removing duplicates 133 articles remained and abstracts were read systematically for eligibility. Only articles published during the last six years were included, as all these three approaches have been practiced during this period. All prospective and retrospective randomized and non-randomized studies concerning TME were included. Articles not sufficiently specifying data about complications and studies combining the procedure with other surgical techniques were excluded. We focused on the following intraoperative and postoperative complications; bleeding, estimated blood loss (EBL), need for blood transfusion, anastomose leakage, urine retention and complication, bladder and urethral injury, urinary tract infection, wound infection, bowel injury, intraabdominal and pelvic abscess and 30-days mortality.

In total, we included 39 studies corresponding to 8094 patients. See the PRISMA flow diagram for detail (**Figure 1**).

RESULTS

The included studies were single center as well as multicenter clinical studies, prospective or retrospective, including several randomized studies. Numerous studies were comparative or case-matched studies, where data originally were compared with open surgery (7-10, 13, 26-30). In six studies, LaTME was compared with RoTME (12, 15, 31-34) while four studies compared LaTME and TaTME (5, 35-37). The rest focused on a single procedure.

The extracted data are presented systematically in **Table 1**.

Indications

The pathology was cancer in all studies except Penna et al (23), who included 86 (out of 720) benign cases. All cancer stages were included though Yamamoto et al (38) and Fuji et al (39) only included stage Tis-T2 tumors, Fleshman et al (29) included T2-T3 and Baik et al (28) included T1-T3. Rouanet et al (40) selected men with narrow pelvis, fatty mesorectum, high BMI, large prostate and presence of fibrosis. Neither if the operation had to be converted into open surgery nor the experience of the surgeon effected if a study was included or not.

Five studies (7, 31, 35, 41, 42) only reported patients treated with neoadjuvant therapy while several studies (28, 29, 36, 43) included both cases with and without neoadjuvant treatment.

Peri and postoperative data

Bleeding and estimated blood loss (EBL)

Fernandez-Hevia et al (37) reported one readmission in the LaTME group because of hemorrhage, while Cho et al (12) reported two conversions to open surgery in the LaTME group due to intractable major vessel bleeding. Van der Pas et al (9) reported conversion in six out of 22 cases because of bleeding. Hellan et al (16) reported three cases of bleeding after RoTME. Chen et al (35) subdivided bleeding into presacral bleedings and other bleedings. Another two studies subdivided as intraabdominal or anastomotic bleeding (24, 38).

Two studies found no significant difference in EBL between TaTME and LaTME (35, 36) and three studies found no significant difference between RoTME and LaTME in bleeding or EBL (31, 32, 44). Perdawood (5) reported a lower blood loss for TaTME than LaTME. Penna et al (23) reported an intraoperative blood loss during TaTME of less than 100ml in 61% of the cases, and furthermore reported six cases (1%) of bleeding more than one liter. Serra-Aracil et al (45) reported 158 ml in EBL after TaTME, and proclaimed it lower than the laparoscopic group of the COLOR II trail. Ielpo et al (33) reported the highest EBL = 280 ml for RoTME (range 0-4000ml) while Park et al (34) reported the lowest EBL = 77.6 ml (range 0-700 ml). Two LaTME studies (38, 39) reported EBL of 28 ml and 20 ml respectively.

Overall, 2.9% of the patients had perioperative bleeding during TaTME and a general average EBL at 107.9 ml for every case. 1.1% of the patients had perioperative bleeding during RoTME and an average EBL at 143.7 ml. The LaTME studies reported 1.4% of patients with bleeding and an average EBL at 115.1 ml. See **Table 2** for calculations of the percentage and an overview.

Need for blood transfusion

Approximately 20% required blood transfusion after TaTME in Rouanet et al (40). Lacy et al (24) reported three blood transfusions because of anemia and one due to hemorrhage after TaTME. Another study (38) reported 1,6 % of cases requiring blood transfusion after LaTME. Overall, 5% of patients undergoing TaTME, 2% of patients after RoTME and 2.3% after LaTME had peri or postoperative blood transfusion.

Anastomotic leakage

Five studies reported the diagnosis as a clinical suspicion where different criteria were reported; fever and pain, pus, gas or fecal discharge from the drain, pelvic abscess and peritonitis (9, 10, 31, 33, 46). After TaTME, Penna et al (23) reported 32 cases identified early and eight cases

identified after 30 days. Perdawood (5) reported four patients readmitted after TaTME and one after LaTME because of anastomotic leakage. Penninckx et al (26) subdivided leakage as: minor (14 cases) and major (30 cases) leaks after LaTME. Schiphorst et al (30) reported four out of 46 cases leading to reoperation or fistula as Hu et al (7) reported 3.1% of leakage and concluded that LaTME after neoadjuvant CRT is a safe procedure. Cho et al (12) reported no early postoperative difference between LaTME vs RoTME while Chen et al (47) reported no statistically significant difference in leakage rates between the TaTME and LaTME groups. As for postoperative pelvic abscess formation.

Overall 5.8% of the patients after TaTME, 8.0% after RoTME and 6.9% after LaTME had anastomotic leakage.

Urine retention and complications

Kang et al (48) defined voiding difficulty as urinary retention or urinary incontinence requiring urological medication or reinsertion of a Foley catheter. Tuech et al (46) reported five patients (8.9%) with postoperative urinary retention, all treated by temporary urethral catheterization. After three months, all patients reported normal urinary function. Kang et al (49) reported two urinary retentions during TaTME and one (47) reported three cases of urinary retention after removing the Foley catheter after LaTME and none after TaTME. Five cases of neurogenic urinary retention were reported after LaTME in one study (38).

In summary, 4.7% after TaTME, 4.9% after RoTME and 2.5% after LaTME had urinary retention or complications.

Bladder and urethral injury

Penna et al (23) reported five cases of urethral injuries (0.7%) and two bladder injuries (0.3%) during perineal dissection after TaTME while Kang et al (49) reported one urethral injury as a result of dissecting too anteriorly into an enlarged prostate. Rasulov et al (43) reported one bladder injury during TaTME, which was closed laparoscopically and the patient was discharged with a urinary catheter, removed one week later. Park et al (34) reported one case of bladder injury because of tumor adhesion to the bladder as well responsible for conversion from RoTME to LaTME. One study (16) reported five genitourinary injuries after RoTME as just one out of two RoTME studies mentioning ureter or bladder injuries. Gong et al (13) reported one conversion from LaTME to open surgery due to ureteric injury.

Overall, five bladder injuries and seven urethral injuries (1.5%) among 806 patients after TaTME were reported. 1.1% of the patients undergoing RoTME and 1.1% of the patients undergoing LaTME had intraoperative urethral or bladder injuries.

Urinary tract infection

Chen et al (35) reported as only TaTME-study one case among 50 patients and Levic et al (17) as the only RoTME-study none cases of urinary infection among 52 patients. Baik et al (28) reported two cases of grade three and one case of grade two urinary tract infection after LaTME. Concerning LaTME, 2.3% among 2814 patients suffered from postoperative urinary tract infection.

Wound infection

Several studies (37, 42, 50, 51) emphasized that the TaTME procedure frequently allows specimen exteriorization without an abdominal incision, eliminating abdominal site morbidity as wound infection and hernia during specimen extraction. Yamamoto et al (38) reported that wound infections was diagnosed within 30 days of the operation according to the criteria of the Centers for Disease Control and Prevention.

1.6% of the patients after TaTME, 1.9% after RoTME and 5.1% after LaTME suffered from wound infection.

Bowel injury

Perdawood (5) reported none bowel injury after TaTME. Two studies (12, 16) reported eight cases (1.1%) after RoTME, besides accentuated one patient that required conversion from RoTME to LaTME because of bowel perforation. Three studies (5, 9, 12) reported 0.8% of patients among 1002 patients after LaTME.

Intraabdominal abscess

Fifteen cases of pelvic or abdominal abscess without evidence of anastomotic leakage were reported by Penna et al (23), listed under intraabdominal abscess in our tables. Van der Pas (9) reported just abscess, listed as intraabdominal. Saklani et al (31) categorized intraabdominal abscess as a severe complication together with anastomotic leakage. Two studies (32, 34) reported no significant difference between RoTME and LaTME.

Overall 2.3% of patients after TaTME, 1.4% after RoTME and 4.3% after LaTME had intraabdominal abscesses.

Pelvic abscess

Chen et al (35) reported three cases of pelvic abscess (8%) in the TaTME group and four cases (6%) in the LaTME group, all treated with antibiotics. Burke et al (42) reported four cases among 50 patients and two readmissions because of pelvic collection after TaTME. All leaks and pelvic collections were managed conservatively with antibiotics and prolonged drainage by Leong et al (52). Baik et al (28) graded it as a serious condition since one patient was hospitalized for 167 days because of pelvic abscess. Kang et al (48) reported no significant difference neither RoTME nor LaTME groups regarding pelvic abscess.

Overall, 9.2% of the patients after TaTME, 1.9% after RoTME and 3.1% after LaTME had pelvic abscess.

30-days mortality

TaTME: Four studies (36, 42, 43, 51) concluded no postoperative mortality and two studies (36, 50) reported no surgery-associated deaths. Penna et al (23) reported 0.5% 30-days mortality and concluded to be similar according to previous rectal surgery trials. Muratore et al (53) reported a patient that died of myocardial infarction three days after surgery. Three studies (5, 35, 37) did not mention mortality while Serra-Aracil (45) reported no 30-days mortality but a six percent median score on the CROPOSSUM scale. Overall, 2.1% patients died during the first 30 days after surgery.

RoTME: Two studies (34, 44) reported none cases of postoperative death without mentioning the follow-up period, while ten studies reported no cases in a follow-up period between 30 days and 3 years. Overall, one patient among 1414 (0.1%) died within the first 30 days.

LaTME: Van der Pas (9) reported eight cases of death within 28 days. Penninckx et al (26) reported 11 cases among 764 patients (1,44%) while Yamamoto et al (38) reported the lowest mortality; none cases among 490. Overall 0.8% of the patients died during the first month after surgery.

DISCUSSION

Complications and mortality due to surgery are of major importance and widespread adoption of new surgical methods depends among other things on complication rates and risk of postoperative death. Consequently, the studies management of data is important. One source of potential reporting bias is the retrospective nature of twelve studies in this review. Here the choice of outcomes reported can be influenced by the results, potentially making published results misleading (54). Performance bias due to the experience among surgeons is another limiting factor as well as the number of surgeons performing the procedures vary from one (13) to 65 different surgeons (29). Several studies (12, 23, 24, 29, 32, 33, 43, 49, 55) reported complications using the Clavien-Dindo classification, which impeded the use of data in relation to our study design.

Different diagnostic criteria and treatment options for the anastomotic leakage have been used throughout the studies (9, 10, 31, 33, 46). However, more cases of leakage in the *RoTME* group compared to the *TaTME* and *LaTME* were reported. The anastomosis seemed to perform more efficiently after *TaTME* with lower number of leaks. The seriousness of the cases was however unclear. Unfortunately, only readmission or not after anastomotic leakage have been reported, while the length of hospitalization and death has not (5, 23, 30, 42). The *LaTME*-group advanced with well experienced surgeons because of the longer use of laparoscopic approach (56), though no superior data found as compared with *TaTME*. Opposite, the *LaTME* performed better in relation to urine retention than *RoTME* and *TaTME*. Urine retention is a complication due to the operative procedure with iatrogenic injuries on the autonomic nerve in the narrow pelvic area (49), as well as the epidural analgesia which often is used during abdominal surgery (57). Nevertheless, patients mostly recovered and gained previously bladder function during weeks after surgery and hospitalization (46), and it was further more deemed to constitute a mild complication (31).

Regarding wound infection, *LaTME* constituted a higher risk of post-operative wound infection, while *TaTME* possibly advantage from the fact that the specimen extraction were done transanal reducing intraabdominal wound related complications (37, 42, 50, 51).

An almost equal percentage of urethral injuries among the three approaches were noted, as well as no higher percentage of injuries on nearby organs like bowel and bladder. Nevertheless, previous studies (58) reported the *TaTME* procedure to cause more cases of urethral injuries.

Like injuries on organs, pelvic and intraabdominal abscess is a severe complication, which can lead to reoperation (23, 37, 42). The reported cases in the *TaTME* varied from 2.4% to 20% (23, 35, 59) what clearly underline the need for further research including big randomized trials. As well the indication for blood transfusion varied among the studies, well-illustrated by Liang et al (8) who transfused four patients out of 169 while Schiphorst et al (30) transfused ten out

of 86. The need for blood transfusion generally followed the bleedings and blood loss, but uniformed international evidence-based guidelines according to indication for blood transfusion might reduce bias.

More bleeding and need for blood transfusion were reported among TaTME and presents a potential serious condition, with a need for acute conversion to open surgery (9, 12, 37). We calculated an average EBL for each one of the approaches, which possible distorted the accuracy, though gave us an opportunity to make a comparison. The average EBL was higher among RoTME than TaTME and LaTME. Baik et al (14) pointed, that prompt open conversion is impossible during RoTME because removing the robotic system is a time-consuming procedure, which is sometimes necessary for immediate control of serious bleeding. A fact that possible influence a higher blood loss during especially the most difficult RoTME operations ending up with conversion.

The TaTME had a higher 30-days mortality rate than RoTME and LaTME, with poor evidence concerning cause of death. A recently published TaTME-study concluded no higher mortality according to previous rectal surgery trials (23). However, research with longer follow-up period is needed since TaTME is a new technique meaning that surgeons improved in the studies (5, 23, 36, 49) and possibly reduced the complication rate in step with gaining higher level of experience.

CONCLUSION

We exposed an extract of complications in minimal invasive surgery for rectal cancer. The TaTME, as the newest procedure, had equal percentage of urethral injuries compared to LaTME and RoTME besides a low rate of anastomotic leakage. On the other hand, RoTME presented a lower percentage of bleeding and 30-days mortality in compare to especially TaTME. Further research is required, ideally randomized studies, to compare the three procedures regarding rates of serious intra and postoperative complications besides comparing their pathological results. Also, focus on which procedure who best treats a specific tumor stage, location and type of patient could possibly reduce complications and postoperative mortality in the future.

ACKNOWLEDGMENTS

Dr Benjamin Thinggard has no conflicts of interest or financial ties to disclose.

Dr Sharaf Karim Perdawood has no conflicts of interest or financial ties to disclose.

REFERENCES

1. NORDCAN AotNCR. Kræftstatistik: Nøgletal og figurer Danmark – Endetarm og anus. 2014.
2. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. *Archives of surgery (Chicago, Ill : 1960)*. 1998;133(8):894-9.
3. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? *Br J Surg*. 1982;69(10):613-6.
4. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet (London, England)*. 1986;1(8496):1479-82.
5. Perdawood SK, Al Khefagie GA. Transanal vs laparoscopic total mesorectal excision for rectal cancer: initial experience from Denmark. *Colorectal Dis*. 2016;18(1):51-8.
6. Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25(21):3061-8.
7. Hu JJ, Liang JW, Wang Z, Zhang XM, Zhou HT, Hou HR, et al. Short-term outcomes of laparoscopically assisted surgery for rectal cancer following neoadjuvant chemoradiotherapy: a single-center experience. *J Surg Res*. 2014;187(2):438-44.
8. Liang X, Hou S, Liu H, Li Y, Jiang B, Bai W, et al. Effectiveness and safety of laparoscopic resection versus open surgery in patients with rectal cancer: a randomized, controlled trial from China. *J Laparoendosc Adv Surg Tech A*. 2011;21(5):381-5.
9. van der Pas MH, Haglind E, Cuesta MA, Furst A, Lacy AM, Hop WC, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *The Lancet Oncology*. 2013;14(3):210-8.
10. Lujan J, Valero G, Biondo S, Espin E, Parrilla P, Ortiz H. Laparoscopic versus open surgery for rectal cancer: results of a prospective multicentre analysis of 4,970 patients. *Surg Endosc*. 2013;27(1):295-302.
11. Group COoSTS. A comparison of laparoscopically assisted and open colectomy for colon cancer. *The New England journal of medicine*. 2004;350(20):2050-9.
12. Cho MS, Baik SJ, Hur H, Min BS, Baik SH, Lee KY, et al. Short and long-term outcomes of robotic versus laparoscopic total mesorectal excision for rectal cancer: a case-matched retrospective study. *Medicine*. 2015;94(11):e522.
13. Gong J, Shi DB, Li XX, Cai SJ, Guan ZQ, Xu Y. Short-term outcomes of laparoscopic total mesorectal excision compared to open surgery. *World J Gastroenterol*. 2012;18(48):7308-13.
14. Baik SH, Kwon HY, Kim JS, Hur H, Sohn SK, Cho CH, et al. Robotic versus laparoscopic low anterior resection of rectal cancer: short-term outcome of a prospective comparative study. *Ann Surg Oncol*. 2009;16(6):1480-7.
15. D'Annibale A, Pernazza G, Monsellato I, Pende V, Lucandri G, Mazzocchi P, et al. Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. *Surg Endosc*. 2013;27(6):1887-95.
16. Hellan M, Ouellette J, Lagares-Garcia JA, Rauh SM, Kennedy HL, Nicholson JD, et al. Robotic Rectal Cancer Resection: A Retrospective Multicenter Analysis. *Ann Surg Oncol*. 2015;22(7):2151-8.
17. Levic K, Donatsky AM, Bulut O, Rosenberg J. A Comparative Study of Single-Port Laparoscopic Surgery Versus Robotic-Assisted Laparoscopic Surgery for Rectal Cancer. *Surg Innov*. 2015;22(4):368-75.
18. Baik JH, Pastor C, Pigazzi A. Robotic and laparoscopic total mesorectal excision for rectal cancer: a case-matched study. *Surg Endosc*. 2011;25(2):521-5.
19. Bianchi PP, Ceriani C, Locatelli A, Spinoglio G, Zampino MG, Sonzogni A, et al. Robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncological safety and short-term outcomes. *Surg Endosc*. 2010;24(11):2888-94.
20. Schootman M, Hendren S, Ratnapradipa K, Stringer L, Davidson NO. Adoption of Robotic Technology for Treating Colorectal Cancer. *Diseases of the colon and rectum*. 2016;59(11):1011-8.
21. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis. *Ontario health technology assessment series*. 2010;10(27):1-118.
22. Collinson FJ, Jayne DG, Pigazzi A, Tsang C, Barrie JM, Edlin R, et al. An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. *International journal of colorectal disease*. 2012;27(2):233-41.
23. Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, et al. Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases. *Ann Surg*. 2016.

24. Lacy AM, Tasende MM, Delgado S, Fernandez-Hevia M, Jimenez M, De Lacy B, et al. Transanal Total Mesorectal Excision for Rectal Cancer: Outcomes after 140 Patients. *J Am Coll Surg*. 2015;221(2):415-23.
25. Mother D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. 2009.
26. Penninckx F, Kartheuser A, Van de Stadt J, Pattyn P, Mansvelt B, Bertrand C, et al. Outcome following laparoscopic and open total mesorectal excision for rectal cancer. *Br J Surg*. 2013;100(10):1368-75.
27. Wu WX, Sun YM, Hua YB, Shen LZ. Laparoscopic versus conventional open resection of rectal carcinoma: A clinical comparative study. *World J Gastroenterol*. 2004;10(8):1167-70.
28. Baik SH, Gincherman M, Mutch MG, Birnbaum EH, Fleshman JW. Laparoscopic vs open resection for patients with rectal cancer: comparison of perioperative outcomes and long-term survival. *Diseases of the colon and rectum*. 2011;54(1):6-14.
29. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. *JAMA*. 2015;314(13):1346-55.
30. Schiphorst AH, Doeksen A, Hamaker ME, Zimmerman DD, Pronk A. Short-term follow-up after laparoscopic versus conventional total mesorectal excision for low rectal cancer in a large teaching hospital. *Int J Colorectal Dis*. 2014;29(1):117-25.
31. Saklani AP, Lim DR, Hur H, Min BS, Baik SH, Lee KY, et al. Robotic versus laparoscopic surgery for mid-low rectal cancer after neoadjuvant chemoradiation therapy: comparison of oncologic outcomes. *Int J Colorectal Dis*. 2013;28(12):1689-98.
32. Yoo BE, Cho JS, Shin JW, Lee DW, Kwak JM, Kim J, et al. Robotic versus laparoscopic intersphincteric resection for low rectal cancer: comparison of the operative, oncological, and functional outcomes. *Ann Surg Oncol*. 2015;22(4):1219-25.
33. Ielpo B, Caruso R, Quijano Y, Duran H, Diaz E, Fabra I, et al. Robotic versus laparoscopic rectal resection: is there any real difference? A comparative single center study. *Int J Med Robot*. 2014;10(3):300-5.
34. Park EJ, Cho MS, Baek SJ, Hur H, Min BS, Baik SH, et al. Long-term oncologic outcomes of robotic low anterior resection for rectal cancer: a comparative study with laparoscopic surgery. *Ann Surg*. 2015;261(1):129-37.
35. Chen CC, Lai YL, Jiang JK, Chu CH, Huang IP, Chen WS, et al. Transanal Total Mesorectal Excision Versus Laparoscopic Surgery for Rectal Cancer Receiving Neoadjuvant Chemoradiation: A Matched Case-Control Study. *Ann Surg Oncol*. 2016;23(4):1169-76.
36. Marks JH, Montenegro GA, Salem JF, Shields MV, Marks GJ. Transanal TATA/TME: a case-matched study of taTME versus laparoscopic TME surgery for rectal cancer. *Techniques in coloproctology*. 2016;20(7):467-73.
37. Fernandez-Hevia M, Delgado S, Castells A, Tasende M, Momblan D, Diaz del Gobbo G, et al. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. *Ann Surg*. 2015;261(2):221-7.
38. Yamamoto S, Ito M, Okuda J, Fujii S, Yamaguchi S, Yoshimura K, et al. Laparoscopic surgery for stage 0/I rectal carcinoma: short-term outcomes of a single-arm phase II trial. *Ann Surg*. 2013;258(2):283-8.
39. Fujii S, Yamamoto S, Ito M, Yamaguchi S, Sakamoto K, Kinugasa Y, et al. Short-term outcomes of laparoscopic intersphincteric resection from a phase II trial to evaluate laparoscopic surgery for stage 0/I rectal cancer: Japan Society of Laparoscopic Colorectal Surgery Lap RC. *Surg Endosc*. 2012;26(11):3067-76.
40. Rouanet P, Mourregot A, Azar CC, Carrere S, Gutowski M, Quenet F, et al. Transanal endoscopic proctectomy: an innovative procedure for difficult resection of rectal tumors in men with narrow pelvis. *Diseases of the colon and rectum*. 2013;56(4):408-15.
41. Araujo SE, da Silva e Sousa AH, Jr., de Campos FG, Habr-Gama A, Dumarco RB, Caravatto PP, et al. Conventional approach x laparoscopic abdominoperineal resection for rectal cancer treatment after neoadjuvant chemoradiation: results of a prospective randomized trial. *Revista do Hospital das Clinicas*. 2003;58(3):133-40.
42. Burke JP, Martin-Perez B, Khan A, Nassif G, de Beche-Adams T, Larach SW, et al. Transanal total mesorectal excision for rectal cancer: early outcomes in 50 consecutive patients. *Colorectal Dis*. 2016;18(6):570-7.
43. Rasulov AO, Mamedli ZZ, Gordeyev SS, Kozlov NA, Dzhumabaev HE. Short-term outcomes after transanal and laparoscopic total mesorectal excision for rectal cancer. *Techniques in coloproctology*. 2016;20(4):227-34.
44. Fernandez R, Anaya DA, Li LT, Orcutt ST, Balentine CJ, Awad SA, et al. Laparoscopic versus robotic rectal resection for rectal cancer in a veteran population. *Am J Surg*. 2013;206(4):509-17.

45. Serra-Aracil X, Mora-Lopez L, Casalots A, Pericay C, Guerrero R, Navarro-Soto S. Hybrid NOTES: TEO for transanal total mesorectal excision: intracorporeal resection and anastomosis. *Surg Endosc.* 2016;30(1):346-54.
46. Tuech JJ, Karoui M, Lelong B, De Chaisemartin C, Bridoux V, Manceau G, et al. A step toward NOTES total mesorectal excision for rectal cancer: endoscopic transanal proctectomy. *Ann Surg.* 2015;261(2):228-33.
47. Chen Y, Guo R, Xie J, Liu Z, Shi P, Ming Q. Laparoscopy Combined With Transanal Endoscopic Microsurgery for Rectal Cancer: A Prospective, Single-blinded, Randomized Clinical Trial. *Surgical laparoscopy, endoscopy & percutaneous techniques.* 2015;25(5):399-402.
48. Kang J, Min BS, Park YA, Hur H, Baik SH, Kim NK, et al. Risk factor analysis of postoperative complications after robotic rectal cancer surgery. *World J Surg.* 2011;35(11):2555-62.
49. Kang L, Chen WH, Luo SL, Luo YX, Liu ZH, Huang MJ, et al. Transanal total mesorectal excision for rectal cancer: a preliminary report. *Surg Endosc.* 2016;30(6):2552-62.
50. Wang Q, Wang C, Sun DH, Kharbuja P, Cao XY. Laparoscopic total mesorectal excision with natural orifice specimen extraction. *World J Gastroenterol.* 2013;19(5):750-4.
51. de Lacy AM, Rattner DW, Adelsdorfer C, Tasende MM, Fernandez M, Delgado S, et al. Transanal natural orifice transluminal endoscopic surgery (NOTES) rectal resection: "down-to-up" total mesorectal excision (TME)--short-term outcomes in the first 20 cases. *Surg Endosc.* 2013;27(9):3165-72.
52. Leong QM, Son DN, Cho JS, Baek SJ, Kwak JM, Amar AH, et al. Robot-assisted intersphincteric resection for low rectal cancer: technique and short-term outcome for 29 consecutive patients. *Surg Endosc.* 2011;25(9):2987-92.
53. Muratore A, Mellano A, Marsanic P, De Simone M. Transanal total mesorectal excision (taTME) for cancer located in the lower rectum: short- and mid-term results. *Eur J Surg Oncol.* 2015;41(4):478-83.
54. Higgins JPT GSe. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011]. The Cochrane Collaboration 2011. Available from: <http://www.handbook.cochrane.org/>.
55. Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. *Annals of Surgery.* 2004;240(2):205-13.
56. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AMH, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *The Lancet.* 2005;365(9472):1718-26.
57. Simmons SW, Cyna AM, Dennis AT, Hughes D. Combined spinal-epidural versus epidural analgesia in labour. *The Cochrane database of systematic reviews.* 2007(3):Cd003401.
58. Bjorn MX, Perdawood SK. Transanal total mesorectal excision--a systematic review. *Danish medical journal.* 2015;62(7).
59. Atallah S, Martin-Perez B, Albert M, deBeche-Adams T, Nassif G, Hunter L, et al. Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution. *Techniques in coloproctology.* 2014;18(5):473-80.

Figure 1: Flow diagram of article selection




Table 1

Author	Study design	Pub. year	Procedure	No. of patients	Bleed	aEBL (ml)	Trans	Leak	Urin	Blad	UTI	W inf	Bowel	I abs	P abs	30-d
Lujan et al (11)	Prospective	2013	LaTME	1387	14			81			36	92		85		16
Penninckx et al (26)	Retrospective	2013	LaTME	764				44*								11
Van der Pas et al (10)	Randomized	2013	LaTME	699	22			58*		9		28	6	51		8
Penna et al (23)	Retrospective	2016	TaTME	634				35		7				15		17 ^{aa}
Cho et al (12)	Retrospective	2015	RoTME	278	3	179		32	5		2	1	3	1		0
			LaTME	278	1	147		31	11		1	0	4			1
Yamamoto et al (38)	Prospective	2013	LaTME	490	3	28	8	40	5		11	36		3		0
Fujii et al (39)	Prospective	2012	LaTME	400	2	20	1	33	4		8					0
			LaTME	77	2	100	3	7	1		3					0
Hellan et al (16)	Retrospective	2015	RoTME	425	3	119	5	37	30	5		16	7			1
Kang et al (48)	Prospective	2011	RoTME	389	3		8	27				2			12	0
Fleshman et al (29)	Randomized	2015	LaTME	240	8	256		5		2						2
Park et al (34)	Prospective	2015	RoTME	133		78	1	6	2	1		2		0		0
			LaTME	84		82	3	3	1	1		0		0		0
Liang et al (9)	Randomized	2011	LaTME	169			4	4			1	9		2		0
Chen et al (12)	Prospective	2015	TaTME	50	1	68		3	0	0	1				3	
			LaTME	100	2	88		4	3	1	1				4	
Ielpo et al (33)	Retrospective	2014	RoTME	56		280		4				3		4		0
			LaTME	87		240		3				5		6		0
Lacy et al (24)	Prospective	2015	TaTME	140	5		4	12	3			0				
Saklini et al (31)	Prospective	2013	RoTME	74		180		4				1		0		0
			LaTME	64		210		8				0		2		0
D'Annibel et al (15)	Retrospective	2013	RoTME	50				5								0
			LaTME	50				7								0
Kim et al (59)	Prospective	2012	RoTME	100			3	2								0
Schiphorst et al (30)	Prospective	2014	LaTME	86		200	10	4	2		1	1		4		1
Fernández-Hevia et al (37)	Prospective	2015	TaTME	37	1			2	1							
			LaTME	37	0			4	4							

Yoo et al (32)	Prospective	2015	RoTME	44	2	240		5	4					1		0
			LaTME	26	0	215		0	1						0	
Gong et al (13)	Randomized	2012	LaTME	67		86		1		1		1				
Levic et al (17)	Retrospective	2015	RoTME	56		50		6	1		0				0	0
Tuech et al (46)	Prospective	2015	TaTME	56			2	3	5							0
Baik et al (28)	Prospective	2011	LaTME	54	0	313		4			3	3		0	3	0
Hu et al (8)	Prospective	2014	LaTME	51	0	204	2	1	1		1	2			0	0
Burke et al (42)	Retrospective	2016	TaTME	50		150		3	2	1					4	0
Perdawood, Khefagie (5)	Prospective	2015	TaTME	25		50		2	4				0			
			LaTME	25		100		4	8				2			
Marks et al (36)	Prospective	2016	TaTME	17		282								0		0
			LaTME	17		397								1		0
Serra-Aracil et al (45)	Prospective	2016	TaTME	32		158	0	3								0
Rouanet et al (40)	Prospective	2013	TaTME	30			6	0		2						0
Leong et al (52)	Prospective	2011	RoTME	29	1		4	3	1						1	0
Muratore et al (53)	Retrospective	2015	TaTME	26				2	1							1
Rasulov et al (43)	Prospective	2015	TaTME	22		30			2	1		1				0
Atallah et al (58)	Retrospective	2014	TaTME	20		153		1**				2			4	0
Kang et al (49)	Prospective	2016	TaTME	20		50	2	1	2	1						0
Lacy et al (51)	Prospective	2013	TaTME	20		45										0
Wang et al (50)	Retrospective	2013	TaTME	16	0			0								0
Fernandez et al (44)	Retrospective	2013	RoTME	13		157		1	5							0

Data systematically presented starting with the study counting the largest total number of patients

Bleed: Bleeding	aEBL: average Estimated Blood Loss	Trans: Bloodtransfusion	Leak: Anastomose leak
Urin: Urine retention & complication	Blad: Bladder & urinary injury	UTI: Urinary tract infection	W inf: Wound infection
Bow: Bowel injury	I abs: Intraabdominal abscess	P abs: Pelvic abscess	30: 30-days mortality
*58 out of 461 patients	**1 out of 15 patients	*44 out of 524 patients	^{aa} 17 out of 548 patients

Table 2

Complication	Ta-TME			R-TME			L-TME		
	cases	total	percent	cases	patients	percent	cases	patients	percent
Bleeding	7	243	2,9%	12	1136	1,1%	54	3839	1,4%
EBL average	-	256	107,9 ml	-	1079	143,7 ml	-	2146	115,1 ml
Need for blood transfusion	14	278	5,0%	21	1076	2,0%	31	1357	2,3%
Anastomotic leakage	67	1151	5,8%	132	1647	8,0%	346	4982	6,9%
Urine retention & complication	20	426	4,7%	48	978	4,9%	41	1654	2,5%
Bladder and urethral injury	12	806	1,5%	6	558	1,1%	14	1241	1,1%
Urinary tract infection	1	50	2,0%	0	56	0,0%	65	2814	2,3%
Wound infection	3	182	1,6%	26	1355	1,9%	178	3516	5,1%
Bowel Injury	0	25	0,0%	8	703	1,1%	8	1002	0,8%
Intraabdominal abscess	15	651	2,3%	8	585	1,4%	158	3642	4,3%
Pelvic abscess	11	120	9,2%	14	752	1,9%	7	223	3,1%
30-days mortality	18	857	2,1%	1	1414	0,1%	39	5044	0,8%

cases: the number of patients reported with the complication
total: the number of patients reported with or without the complication
percent: the percent of cases among the total number of patients
EBL average in mililiter blood (not percent)